The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
about
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implicationsFeasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBMO6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Tumour-infiltrating T-cell subpopulations in glioblastomas.Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytomaRadiation necrosis following treatment of high grade glioma--a review of the literature and current understanding.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastomaMGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRIdentification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinomaMolecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.Double-labelling immunohistochemistry for MGMT and a "cocktail" of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours.Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.Clinico-pathological feature of pilomyxoid astrocytomas: three case reports.Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.MGMT promoter methylation in non-neoplastic brain.The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
P2860
Q26829663-AF238F23-E66A-4FD4-B914-4CDB78DE37CEQ33433682-9B2FEABC-98DA-455D-947D-0A0BDEF374F1Q33797741-7791FE9D-BDD2-4644-A24A-E0A78C79B05FQ33804528-EC4EDBB0-1922-4AD8-8D9D-2E1952204FF1Q33943553-E0935D6E-FA0E-461C-9325-4F976E053F9FQ33977312-7BAD4A24-7D31-4DF3-9B15-780486B8F616Q34087196-16EA2C15-B4A0-493C-BCDC-EEE9B59E8FB1Q34478948-1039F13C-69FF-4B05-90D5-40C004F89E9EQ35232507-5F4E7961-DF01-4CBB-9302-A49F0679D5B5Q35850389-879E2D8C-B767-49CC-AD5C-471D627D9C08Q36216177-0E89F813-3997-4527-861C-C78A8C5CA91FQ36252167-A13B7DF6-5B94-41E9-B1E1-C637CF6FB534Q36299167-51B7A347-D5BB-4915-B101-2B83C50D7CE2Q36347256-A61C31E3-503C-4138-823A-971FD76F4783Q36486875-28F0FED9-2925-4445-ADF0-81BDF988A089Q36552798-AD3BDEE9-9777-49DB-97DC-570283A3ECEAQ36627170-954D60A3-F634-44DA-8EB9-423E5D0434FCQ37485637-146D3C69-D39E-433B-AB3E-21F9F619D933Q37861732-501004AA-868A-462A-B705-61513E272ECFQ37992191-46DE779E-894F-496C-A6CC-CED72843018BQ38044236-0D6266BA-3BB9-4BF6-A89E-218955AF9719Q38675705-2D464746-8EE0-432C-AA26-4032F87DFC8CQ38919700-044C9320-E84B-40B5-8A54-F122EDE54A94Q39406816-53ABD871-F208-4946-9935-DE87A8C38989Q39967271-2B413E92-D481-4A37-9E1F-FF15D14C89B3Q40603254-701F9CAD-C5BE-4240-BDD9-C3D08DAC6F0CQ41756350-2C01751D-5749-4BD2-8B43-B3B5106E99B2Q42364418-EA1B4861-F3AA-4136-9C16-5F452ED3BD95Q42475084-D1F614ED-F953-4CC7-87EF-E814DE02856FQ42752134-64A4AF42-8494-4ADF-8E6E-D005D654E8CFQ44440342-5F802FB1-DDA7-4C9E-9E4A-E222136927FDQ45835773-406FFAFC-859D-499D-8419-4F81FED0BBB3Q47115174-E6D96A5D-8F7F-4136-B495-174A4FFF0B4EQ48116112-99124CB6-ACC4-46F5-9B22-9CE0353E33A6Q48137109-53587E75-765E-498A-A3F7-D1AD58EFEF0AQ48321809-BC25E8EA-3AEC-4E93-B8C1-6E71379C90DCQ48626253-07CECC5E-7DAE-44B0-AF77-775644B00F96Q49093913-02F35452-F7DB-49BB-81E4-224E2CC484B3Q49979233-95F2D6A8-33AA-4190-839A-0EFADC2369B8Q51079367-17FB9D35-3910-45A2-8453-2E81A72ECB4E
P2860
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The correlation and prognostic ...... MGMT protein in glioblastomas.
@en
type
label
The correlation and prognostic ...... MGMT protein in glioblastomas.
@en
prefLabel
The correlation and prognostic ...... MGMT protein in glioblastomas.
@en
P2093
P2860
P1433
P1476
The correlation and prognostic ...... MGMT protein in glioblastomas.
@en
P2093
Chang-Soo Park
Hong-Jae Chae
In-Young Kim
Kyung-Hwa Lee
Kyung-Sub Moon
Sam-Suk Kang
Shu-Guang Jin
Tae-Young Jung
Van Thang Cao
P2860
P304
866-75; discussion 875
P356
10.1227/01.NEU.0000357325.90347.A1
P407
P577
2009-11-01T00:00:00Z